Prediction of progression-free survival and response to paclitaxel plus carboplatin in patients with recurrent or advanced cervical cancer

International Journal of Gynecological Cancer

Volumn 22, Issue 4, 2012, Pages 623-629

  Hisamatsu, Takeshi ^a   Mabuchi, Seiji ^a   Yoshino, Kiyoshi ^a   Fujita, Masami ^a   Enomoto, Takayuki ^a   Hamasaki, Toshimitsu ^b   Kimura, Tadashi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Paclitaxel carboplatin; Prognostic factors; Recurrent cervical cancer; Survival

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PACLITAXEL; PELVIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; UTERINE CERVICAL NEOPLASMS;

EID: 84862988273     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e3182473277     Document Type: Article

References (28)

1. Benedet JL, Odicino F, Maisonneuve P, et al. Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2003;83:41-78.
2. Long HJ 3rd. Management of metastatic cervical cancer: review of the literature. J Clin Oncol. 2007;25:2966-2974.
3. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol. 2004;22:3113-3119.
4. Omura GA, Blessing JA, Vaccarello L, et al. Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1997;15:165-171.
5. Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Gynecologic Oncology Group Study. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23:4626-4633.
6. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649-4655.
7. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748-1756.
8. McGuire WP 3rd, Arseneau J, Blessing JA, et al. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1990;8:755-756.
9. Termrungruanglert W, Kudelka AP, Piamsomboon S, et al. Remission of recurrent cervical cancer with paclitaxel and carboplatin: a case report and review of literature. Eur J Gynaecol Oncol. 1996;17:493-496.
10. Sit AS, Kelley JL, Gallion HH, et al. Paclitaxel and carboplatin for recurrent or persistent cancer of the cervix. Cancer Invest. 2004;22:477-478.
11. Moore KN, Herzog TJ, Lewin S, et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol. 2007;105:299-303.
12. Piver MS, Ghamande SA, Eltabbakh GH, et al. First-line chemotherapy with paclitaxel and platinum for advanced and recurrent cancer of the cervixVa phase II study. Gynecol Oncol. 1999;75:334-337.
13. Secord AA, Havrilesky LJ, Carney ME, et al. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. Int J Clin Oncol. 2007;12:31-36.
14. Tinker AV, Bhagat K, Swenerton KD, et al. Carboplatin and paclitaxel for advanced and recurrent cervical carcinoma: the British Columbia Cancer Agency experience. Gynecol Oncol. 2005;98:54-58.
15. Mabuchi S, Morishige K, Enomoto T, et al. Carboplatin and paclitaxel as an initial treatment in patients with stage IVb cervical cancer: a report of 7 cases and a review of the literature. J Gynecol Oncol. 2010;21:93-96.
16. Mabuchi S, Morishige K, Fujita M, et al. The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy. Gynecol Oncol. 2009;113:200-204.
17. Pectasides D, Fountzilas G, Papaxoinis G, et al. Carboplatin and paclitaxel in metastatic or recurrent cervical cancer. Int J Gynecol Cancer. 2009;19:777-781.
18. Ozols RF, Bundy BN, Greer BE, et al. Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3183-3185.
19. Saito I, Kitagawa R, Fukuda H, et al. A phase III trial of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in stage IVB, persistent or recurrent cervical cancer: Gynecologic Cancer Study Group/Japan Clinical Oncology Group Study (JCOG0505). Jpn J Clin Oncol. 2010;40:90-93.
20. Vermorken JB, Zanetta G, De Oliveira CF, et al. Randomized phase III trial of bleomycin, vindesine, mitomycin-C, and cisplatin (BEMP) versus cisplatin (P) in disseminated squamous-cell carcinoma of the uterine cervix: an EORTC Gynecological Cancer Cooperative Group study. Ann Oncol. 2001;12:967-974.
21. Brooks RA, Rader JS, Dehdashti F, et al. Surveillance FDG-PET detection of asymptomatic recurrences in patients with cervical cancer. Gynecol Oncol. 2009;112:104-109.
22. Moore DH, Tian C, Monk BJ, et al. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2010;116:44-49.
23. Tanioka M, Katsumata N, Yonemori K, et al. Second platinum therapy in patients with uterine cervical cancer previously treated with platinum chemotherapy. Cancer Chemother Pharmacol. 2010;68:337-342.
24. Bahadori HR, Green MR, Catapano CV. Synergistic interaction between topotecan and microtubule-interfering agents. Cancer Chemother Pharmacol. 2001;48:188-196.
25. Tiersten AD, Selleck MJ, Hershman DL, et al. Phase II study of topotecan and paclitaxel for recurrent, persistent, or metastatic cervical carcinoma. Gynecol Oncol. 2004;92:635-638.
26. Tewari KS, Monk BJ. The rationale for the use of non-platinum chemotherapy doublets for metastatic and recurrent cervical carcinoma. Clin Adv Hematol Oncol. 2010;8:108-115.
27. Wright JD, Viviano D, Powell MA, et al. Bevacizumab combination therapy in heavily pretreated, recurrent cervical cancer. Gynecol Oncol. 2006;103:489-493.
28. Kitchener HC, Hoskins W, Small W Jr, et al. Cervical Cancer Consensus Group. The development of priority cervical cancer trials: a Gynecologic Cancer InterGroup report. Int J Gynecol Cancer. 2010;20:1092-1100.